This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
What research shows about methylene blue and mitochondria
In cell and animal studies, methylene blue acts as an alternative electron carrier in mitochondria, the main energy producers inside cells. Human studies of methylene blue remain limited, and no clinical trial has shown a benefit for mitochondrial dysfunction.
Methylene blue and mitochondrial peptides are both studied for effects on how cells make and use energy. Mitochondrial-derived peptides, small peptides encoded in mitochondrial DNA, improved insulin sensitivity in rodent studies, and whether they can become human therapies is not yet known. The electron-carrier idea starts with how mitochondria normally pass electrons.
Methylene blue acts as an alternative mitochondrial electron carrier
In cell studies, methylene blue works as an alternative electron carrier, a molecule that moves electrons outside the usual route. Methylene blue cycles between two chemical forms, taking electrons from NADH-using enzymes to become leucomethylene blue. Leucomethylene blue then hands those electrons to cytochrome c, a protein that feeds the chain's final step.
The usual route is the electron transport chain, a series of protein complexes inside mitochondria. NADH and FADH2, electron carriers made as cells break down fuel, donate electrons at Complexes I and II. Electrons then pass through Complex III and cytochrome c to Complex IV. That electron flow drives the production of ATP, the molecule cells run on, and also generates oxidants.
Key results for the electron-cycling model come from one line of human fibroblasts grown in culture. In those cells, methylene blue raised Complex IV activity by 30% and delayed senescence, the point where cells stop dividing. No outcome was measured in a living animal or a person.
Methylene blue's effects also follow a hormetic, or two-phase, dose pattern. Low doses cycle electrons through the chain, while high doses can produce opposite effects.
That lab work also fed Alzheimer's research on tau, a brain protein that forms tangles.
Methylene blue tau research led to the LMTM trials
Laboratory and animal studies of methylene blue and tau led to two phase 3 Alzheimer's trials of LMTM, a related compound. In their randomized comparisons, neither trial showed a benefit on its primary outcomes.
In cell and animal reports, methylene blue reduced plaque and tangle formation and partly restored mitochondrial function. In mice carrying human tau, methylene blue preserved memory in one of two models, and only when started before symptoms.
LMTM, short for leuco-methylthioninium, is a separate compound, a stable reduced form of the molecule in methylene blue. In a 15-month phase 3 trial of 891 adults with mild to moderate Alzheimer's disease, LMTM showed no benefit on thinking or daily function.
A separate 18-month trial of 800 adults found differences only in a revised analysis of non-randomized groups taking LMTM alone. That exploratory result still needs a randomized trial to confirm it.
Smaller human studies took a different approach, imaging the brain after methylene blue itself.
Human imaging studies of methylene blue are small
Human imaging studies of methylene blue gave single doses to small groups and tracked short-term brain changes. None tested lasting effects on memory, and the researchers called for larger studies.
In a placebo-controlled study of 26 healthy adults, one oral dose of methylene blue raised activity in attention and short-term memory regions. One hour later, correct memory-retrieval answers rose 7%. A companion study in 28 healthy adults found stronger resting brain connectivity.
In healthy people and rats, intravenous methylene blue lowered brain blood flow and energy use, contrary to the researchers' expectations. In 42 adults with claustrophobia, methylene blue after exposure therapy had mixed effects on fear one month later.
With human data this thin, most mitochondrial evidence still comes from cell and animal work.
Get 100+ biomarkers tested
One blood draw a year. A full picture of your health, explained in plain language.
Get 100+ biomarkers tested
One blood draw a year. A full picture of your health, explained in plain language.
Methylene blue's mitochondrial evidence remains mostly preclinical
The strongest evidence for methylene blue's mitochondrial effects comes from cell and animal studies. Randomized trials in mitochondrial disorders have found no clear benefit for any intervention. Methylene blue was not among those tested.
In lab experiments, methylene blue routed electrons around blocked steps in the chain and protected cultured neuronal cells. A modified version lacking its electron-carrying site had no effect on the chain. Methylene blue also limited damage in rat models of Parkinson's disease and stroke.
Reviewers have proposed that methylene blue protects cells by supporting Complex IV and heme production, a hypothesis built largely on cell studies. Both processes are impaired in Alzheimer's brains.
| Evidence type | What exists | Status |
|---|---|---|
| Cell and animal studies | Electron carrying, Complex IV support, and protection of neuronal cells against several toxins, though not against direct oxidative stress | Preclinical only |
| Human imaging | Single-dose studies in small groups of healthy adults; short-term changes in brain activity and blood flow | Preliminary; no lasting outcome measured |
| Confirmatory trials of related compounds | 2 phase 3 LMTM trials missed primary outcomes as randomized; a 2026 phase 3 trial of the same compound, now called hydromethylthionine, found no significant difference on co-primary clinical endpoints at 52 weeks | Not confirmed |
| Use in mitochondrial dysfunction | No trial showing benefit; most mitochondrial diseases lack a targeted therapy; FDA label covers acquired methemoglobinemia only, with no indication for mitochondrial dysfunction, memory, or Alzheimer's disease | None |
Until a human trial measures mitochondrial outcomes, methylene blue's effects on mitochondria remain a research question. Methylene blue's known side effects apply to any use of the drug.
IMPORTANT SAFETY INFORMATION
Provayblue carries a boxed warning: methylene blue may cause serious or fatal serotonin syndrome when used with serotonergic drugs and opioids. The label advises avoiding use alongside selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and opioids.
Contraindications on the label: severe hypersensitivity to methylene blue or any other thiazine dye, and glucose-6-phosphate dehydrogenase (G6PD) deficiency, because of the risk of hemolytic anemia. The FDA-approved Provayblue prescribing information is the authoritative label.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
References
- Yang L, Youngblood H, Wu C, Zhang Q (2020). Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation. *Transl Neurodegener*, *9*(1), 19. https://doi.org/10.1186/s40035-020-00197-z
- Merry TL, Chan A, Woodhead JST, et al (2020). Mitochondrial-derived peptides in energy metabolism. *Am J Physiol Endocrinol Metab*, *319*(4), E659–E666. https://doi.org/10.1152/ajpendo.00249.2020
- Atamna H, Nguyen A, Schultz C, et al (2008). Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. *FASEB J*, *22*(3), 703–12. https://doi.org/10.1096/fj.07-9610com
- Nolfi-Donegan D, Braganza A, Shiva S (2020). Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement. *Redox Biol*, *37*, 101674. https://doi.org/10.1016/j.redox.2020.101674
- Rojas JC, Bruchey AK, Gonzalez-Lima F (2012). Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. *Prog Neurobiol*, *96*(1), 32–45. https://doi.org/10.1016/j.pneurobio.2011.10.007
- Wilcock GK, Gauthier S, Frisoni GB, et al (2018). Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. *J Alzheimers Dis*, *61*(1), 435–457. https://doi.org/10.3233/JAD-170560
- Oz M, Lorke DE, Petroianu GA (2009). Methylene blue and Alzheimer's disease. *Biochem Pharmacol*, *78*(8), 927–32. https://doi.org/10.1016/j.bcp.2009.04.034
- Hochgräfe K, Sydow A, Matenia D, et al (2015). Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. *Acta Neuropathol Commun*, *3*, 25. https://doi.org/10.1186/s40478-015-0204-4
- Gauthier S, Feldman HH, Schneider LS, et al (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. *Lancet*, *388*(10062), 2873–2884. https://doi.org/10.1016/S0140-6736(16)31275-2
- Rodriguez P, Singh AP, Malloy KE, et al (2017). Methylene blue modulates functional connectivity in the human brain. *Brain Imaging Behav*, *11*(3), 640–648. https://doi.org/10.1007/s11682-016-9541-6
- Rodriguez P, Zhou W, Barrett DW, et al (2016). Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. *Radiology*, *281*(2), 516–526. https://doi.org/10.1148/radiol.2016152893
- Singh N, MacNicol E, DiPasquale O, et al (2023). The effects of acute Methylene Blue administration on cerebral blood flow and metabolism in humans and rats. *J Cereb Blood Flow Metab*, *43*(2_suppl), 95–105. https://doi.org/10.1177/0271678X231157958
- Telch MJ, Bruchey AK, Rosenfield D, et al (2014). Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. *Am J Psychiatry*, *171*(10), 1091–8. https://doi.org/10.1176/appi.ajp.2014.13101407
- Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF (2012). Treatment for mitochondrial disorders. *Cochrane Database Syst Rev*, *2012*(4), CD004426. https://doi.org/10.1002/14651858.CD004426.pub3
- Wen Y, Li W, Poteet EC, et al (2011). Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. *J Biol Chem*, *286*(18), 16504–15. https://doi.org/10.1074/jbc.M110.208447
- Atamna H, Kumar R (2010). Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. *J Alzheimers Dis*, *20 Suppl 2*, S439–52. https://doi.org/10.3233/JAD-2010-100414
- Poteet E, Winters A, Yan LJ, et al (2012). Neuroprotective actions of methylene blue and its derivatives. *PLoS One*, *7*(10), e48279. https://doi.org/10.1371/journal.pone.0048279
- Wischik CM, Stefanacci R, Bentham P, et al (2026). Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. *J Prev Alzheimers Dis*, *13*(3), 100480. https://doi.org/10.1016/j.tjpad.2026.100480
- Ball M, van Bergen NJ, Compton AG, Thorburn DR, Rahman S, Christodoulou J (2025). Therapies for Mitochondrial Disease: Past, Present, and Future. *J Inherit Metab Dis*, *48*(4), e70065. https://doi.org/10.1002/jimd.70065
- DailyMed. PROVAYBLUE (methylene blue) injection, prescribing information. US National Library of Medicine. Updated May 2025. Accessed November 11, 2026.
















